Which blood thinner costs less for cancer patients with clots? study investigates.
NCT ID NCT05643885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at medical costs for cancer patients who had a blood clot (VTE) and were treated with either apixaban or low molecular weight heparin. Researchers analyzed insurance claims from over 7,300 patients to compare total healthcare costs, including hospital stays and pharmacy bills. The goal was to see which treatment might be more affordable for patients and the healthcare system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Investigational
New York, New York, 10017, United States